Treatment with deucravacitinib in patients with active PsA showed higher response rates and improvement in quality of life ...
Bristol-Myers Squibb (NYSE:BMY) on Saturday announced results from a late-stage trial for its psoriasis therapy Sotyktu in ...
Yonhap News Agency on MSN2d
Celltrion launches autoimmune disease treatment in U.S.Celltrion Inc., a major South Korean biopharmaceutical firm, said Thursday it has launched its biosimilar product for Stelara ...
Squibb announced positive data from the Phase 3 POETYK PsA-2 trial evaluating the efficacy and safety of Sotyktu in adults ...
Although metabolic syndrome is associated with higher PsA disease activity, it is not associated with higher PsA-related ...
STEQEYMA®, one of the first-wave biosimilars to STELARA®, is now available in the U.S.
US pharma major Bristol Myers Squibb has announced positive data from the pivotal Phase III POETYK PsA-2 trial evaluating the ...
Christian Cottingham-Endter has quite a few chronic conditions that make staying active and eating right a challenge. One of them is psoriatic arthritis. But thanks ...
Zacks.com on MSN3d
PTGX Up as J&J-Partnered Drug Meets Goal in Ulcerative Colitis StudyThe phase IIb ANTHEM-UC study evaluating Protagonist and JNJ's icotrokinra for treating ulcerative colitis meets the primary endpoint.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback